Hema Parmar

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

T. Powles, G. Iyer, A. Necchi, 2024, Journal of Clinical Oncology.